Pfizer to acquire ResApp for $75m.

Pfizer, an American multinational pharmaceutical and biotechnology corporation, to acquire ResApp, a digital healthcare solutions provider, for $75m. "We are excited by the prospect of this acquisition by Pfizer, a leading biopharmaceutical company that shares our vision and belief that technology can help transform healthcare and improve patients’ lives," Tony Keating, ResApp CEO and Managing Director.